Jackson Acquisition Company II Closes IPO, Begins NYSE Trading
Deal News | Dec 13, 2024 | EIN
Jackson Acquisition Company II (NYSE: JACS.U) has successfully closed its initial public offering (IPO), raising a total of $230 million with the sale of 23 million units priced at $10.00 each. This offering reflects the full exercise of the underwriter's over-allotment option. Trading commenced on the New York Stock Exchange under the symbol JACS.U on December 10, 2024. Each unit in the offering consists of one Class A ordinary share and a right to receive one-tenth of an additional Class A ordinary share after completing a business combination. The company, led by Chairman and CEO Richard L. Jackson, is a special purpose acquisition company (SPAC) targeting mergers or acquisitions, particularly within the healthcare sector. Roth Capital Partners served as the sole manager for the offering.
Sectors
- Finance
- Healthcare
- Biotechnology
Geography
- United States – The article discusses events occurring in the U.S., including Jackson Acquisition Company II's IPO on the NYSE.
Industry
- Finance – Relevant as Jackson Acquisition Company II is involved in financial activities related to public offerings and capital markets.
- Healthcare – Pertinent due to Jackson Acquisition Company II's declared focus on merging or acquiring companies within the healthcare sector.
- Biotechnology – BioMedWire, a source mentioned in the article, focuses on developments in the Biotechnology sector.
Financials
- $230,000,000 – Total funds raised from Jackson Acquisition Company II's IPO at $10.00 per unit for 23 million units.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Jackson Acquisition Company II | Target Company | Company | A special purpose acquisition company focused on mergers or acquisitions, with an emphasis on healthcare. |
| Roth Capital Partners | Underwriter | Company | Acted as the sole manager for the IPO of Jackson Acquisition Company II. |
| Richard L. Jackson | Chairman and CEO | Person | Leader of Jackson Acquisition Company II involved in the IPO and strategic direction. |
| BioMedWire | Comunications Platform | Company | Specializes in communications focusing on biotechnology and life sciences sectors. |